Remove tag patent
article thumbnail

Applied DNA Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton Tagging

BioTech 365

– Newly allowed Patent Protects Methods of Tagging Cotton Fibers During Ginning Process – STONY BROOK, N.Y.–(BUSINESS –(BUSINESS WIRE)–$APDN #COVID19–Applied DNA Sciences, Inc.

DNA 52
article thumbnail

Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court

Pharmaceutical Technology

Amgen could be the winner of a high-stakes patent spat with Sanofi as tensions run high weeks before the March 27 US Supreme Court hearing. The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs come with a high price tag.

Antibody 262
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: A Supreme Court review of a contentious patent issue would change the way pharma claims discoveries

STAT News

In the coming weeks, the Supreme Court is expected to decide whether to review a wonky, but exceedingly important, debate over patents that has the pharmaceutical industry on edge. At issue is the extent to which a drug company must describe how to replicate its newly invented medicines when applying for patents, notably biologics.

article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Peptide nano-particle conjugates. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 130
article thumbnail

FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar

pharmaphorum

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

article thumbnail

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

pharmaphorum

C5 inhibitor Soliris – which has a list price in the US of more than $500,000 per year – has been a standard therapy for the rare disorder since 2007, and was joined on the market by longer-acting follow-up Ultomiris in 2018 which launched with a price tag of around $450,000 per year. billion and $1.1

Drugs 52
article thumbnail

What challenges does the advanced therapies sector face? 

Drug Discovery World

Intellectual property: High patent royalties and licensing fees for key technologies can inflate treatment costs. Other Challenges: Limited insurance coverage: Many insurance companies are hesitant to cover CGTs due to their high price tags and limited long-term data.